The GLP-1 compounding market changed dramatically in 2025. Here is the short version, current as of November 2026: neither tirzepatide nor semaglutide is on the FDA drug shortage list, FDA enforcement discretion for compounders ended in spring 2025, and compounded versions are legal only as patient-specific prescriptions from licensed 503A pharmacies, never as routine copies of Wegovy, Ozempic, Zepbound or Mounjaro. Compounded GLP-1s are not FDA-approved; branded Wegovy and Zepbound are.
This guide covers the key regulatory changes, what they mean for your practice, and practical strategies for running a sustainable GLP-1 weight loss program in 2026.
Timeline: What Happened
The Shortage Era (2022-2025)
The GLP-1 story starts with unprecedented patient demand. As semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) gained mainstream attention for weight loss, demand far exceeded supply from the brand manufacturers Novo Nordisk and Eli Lilly.
In 2022 the FDA added semaglutide and tirzepatide to the drug shortage list, which triggered an important legal exception: under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a drug in shortage is not treated as commercially available, so compounders can make copies of it.
This opened the door for compounding pharmacies to produce semaglutide and tirzepatide, creating a secondary market of compounded GLP-1 medications. Thousands of medical practices built weight loss programs around compounded semaglutide, often at significantly lower patient cost than brand-name alternatives.
October 2024 to March 2025: Tirzepatide Comes Off the List
The FDA declared the tirzepatide shortage resolved on October 2, 2024. After a compounding trade group sued, the agency re-evaluated and reaffirmed the decision on December 19, 2024. A federal district court denied the group’s request for a preliminary injunction on March 5, 2025, which ended FDA enforcement discretion for 503A pharmacies. 503B outsourcing facilities had until March 19, 2025.
February to May 2025: Semaglutide Follows
On February 21, 2025, the FDA announced that the semaglutide shortage had resolved. The court again declined to block the decision, denying a preliminary injunction on April 24, 2025, which ended enforcement discretion for 503A pharmacies. 503B outsourcing facilities had until May 22, 2025.
Current Status (November 2026)
- Neither drug is in shortage. In an April 1, 2026 statement, the FDA confirmed that semaglutide and tirzepatide appear on neither its drug shortage list nor the 503B bulks list.
- 503B outsourcing facilities generally cannot compound either drug, because they can only use bulk substances that are on the 503B bulks list or in shortage.
- 503A pharmacies can compound semaglutide or tirzepatide only against an individual patient’s prescription, and not as an essentially-copy of the brand-name drug unless the prescriber documents a change that makes a significant difference for that patient.
- Compounded GLP-1s are not FDA-approved, and the FDA has sent warning letters over marketing that calls them generic or the same as Wegovy, Ozempic or Zepbound.
- Brand-name Wegovy and Zepbound are FDA-approved for chronic weight management and available through standard pharmacy channels.
Understanding the Regulatory Pathways
503A: Patient-Specific Compounding
503A pharmacies compound medications based on individual patient-specific prescriptions. Their authority comes from Section 503A of the FD&C Act and is primarily regulated by state pharmacy boards.
Key points for GLP-1 compounding:
- Patient-specific only. Every 503A compound starts with a prescription for a named patient. While a brand-name drug is in shortage, 503A pharmacies may make copies of it; now that semaglutide and tirzepatide are not in shortage, that exception is closed.
- “Essentially a copy” rule. A 503A pharmacy cannot regularly compound a drug that is essentially a copy of a commercially available product (same active ingredient, similar strength, same route) unless the prescriber documents a change that produces a significant difference for the identified patient.
- State-level variation. State pharmacy boards interpret and enforce compounding regulations differently. What is permitted in one state may not be in another.
- Prescriber relationship required. 503A compounding requires a valid patient-specific prescription from a licensed prescriber with a documented patient relationship.
503B: Outsourcing Facilities
503B outsourcing facilities are FDA-registered and can compound in larger batches, but their ability to compound copies of commercially available drugs is limited:
- Shortage exception closed for both drugs. 503B facilities can compound from bulk only when the substance is on the FDA’s bulk drug substances list or the drug is in shortage. Semaglutide and tirzepatide are neither, so 503B facilities generally cannot compound them.
- FDA inspection and oversight. 503B facilities face more rigorous federal oversight than 503A pharmacies, including FDA inspections and cGMP requirements.
Brand-Name Prescribing
Prescribing brand-name Ozempic, Wegovy, Mounjaro, or Zepbound remains straightforward:
- No compounding regulatory complexity. You are prescribing an FDA-approved medication through standard pharmacy channels.
- Higher patient cost. Without insurance coverage, brand-name GLP-1 medications cost significantly more than compounded alternatives. Manufacturer savings programs exist but have eligibility requirements.
- Supply stability. Brand-name supply has largely stabilized since the acute shortage period, though availability can vary by dosage strength and region.
How Practices Should Adapt
The practices that are thriving in 2026 are the ones that built flexible programs rather than depending on a single compounding pathway.
Strategy 1: Multi-Pharmacy Relationships
Do not rely on a single pharmacy partner. Build relationships with multiple pharmacies across different regulatory pathways:
- A 503A pharmacy that has a defensible pathway for GLP-1 compounding
- A 503B facility for medications where they have clear authority (peptides, hormones, non-GLP-1 compounds)
- Brand-name prescribing capability as a fallback or premium option
This gives you supply chain resilience regardless of how the regulatory environment evolves. See our guide to choosing pharmacy partners for a detailed evaluation framework.
Strategy 2: Diversify Beyond GLP-1
The GLP-1 compounding restrictions reinforced an important lesson: programs dependent on a single therapy type are vulnerable. Practices that diversified into adjacent programs absorbed the GLP-1 changes more easily.
Peptide therapy is the most natural complement to GLP-1 weight loss. With the expected FDA peptide reclassification, peptide therapy programs are poised for growth. The patient demographic overlaps significantly with GLP-1 patients.
Testosterone replacement therapy (TRT) and hormone replacement therapy (HRT) serve different patient populations but share the same operational infrastructure: patient intake, provider review, compounding pharmacy fulfillment, and automated follow-up.
Running multiple programs from a single platform means the infrastructure investment for your first program pays dividends across every additional program you add.
Strategy 3: Build on a Flexible Platform
Your technology platform should make it easy to adapt as regulations change:
- Multi-pharmacy routing so you can switch pharmacy sources without changing your workflow
- Program-agnostic infrastructure that supports GLP-1, peptides, TRT, and HRT from the same system
- Intake and prescribing flexibility so adding a new therapy does not require building new infrastructure
- Pharmacy integration that handles the routing and fulfillment complexity for you
Practices that built custom workflows tied to a single pharmacy or therapy type are the ones scrambling to adapt. Practices on flexible platforms simply adjust their pharmacy routing and continue operating.
Strategy 4: Stay Informed
The regulatory environment is not static. Stay current on:
- FDA enforcement actions and guidance related to compounding
- Court decisions that may expand or restrict compounding authority
- State pharmacy board updates for states where you practice or have patients
- Industry group communications from organizations like the Alliance for Pharmacy Compounding and relevant medical societies
Your pharmacy partners should be a source of regulatory intelligence. Good pharmacy partners proactively communicate about changes that affect your prescribing.
What This Means for Your Weight Loss Program
If you are running a GLP-1 weight loss program or considering starting one, here is the practical takeaway:
GLP-1 weight loss programs are still viable and profitable. The regulatory changes affected the compounding supply chain, not the clinical viability or patient demand for medical weight loss. Patients still want medically supervised weight loss programs. The question is how you source the medication and structure the program.
Build for flexibility. Design your program to work across multiple GLP-1 sources: compounded (where legally available), brand-name, and potentially new entrants as the market evolves.
Complement with adjacent programs. Peptide therapy, TRT, and HRT share infrastructure and patient demographics with GLP-1 weight loss. Offering multiple programs reduces your dependence on any single therapy.
Use technology to manage complexity. Multi-pharmacy routing, automated patient follow-up, and integrated prescribing workflows make it possible to run a flexible program without proportionally increasing administrative overhead.
How Karpa Health Helps
Karpa Health is built for exactly this kind of regulatory flexibility. The platform supports:
- Compliant GLP-1 prescribing. Independent licensed providers in Karpa’s 50-state network prescribe compounded semaglutide or tirzepatide only when a patient needs something the brand-name product doesn’t offer, and licensed 503A pharmacies fill each patient-specific prescription. Both follow current FDA compounding guidelines and state board rules.
- GLP-1 weight loss programs with compounded options plus branded Wegovy and Zepbound for patients who want an FDA-approved product
- Peptide therapy programs built on the peptides that are compoundable today
- TRT and HRT programs from the same platform
- streamlined provider review that reduces provider time per patient regardless of the therapy type
- Automated patient follow-up that keeps patients on protocol across all programs
The platform adapts as regulations change. When a pharmacy pathway opens or closes, you adjust your routing without rebuilding your program infrastructure.
Book a demo to see how Karpa Health supports flexible GLP-1 and multi-program practices.
Book a call with Karpa Health if you want help structuring the right program. If you are still choosing infrastructure, see how the main options compare in the best GLP-1 and peptide platforms roundup.
